Table 3.
Cumulative incidence functions for subsequent invasive breast cancer after diagnosis of lobular carcinoma in situ.
| Characteristics | Overall CIF (95 % CI) |
CIF for ipsilateral IBC (95 % CI) |
CIF for contralateral IBC (95 % CI) |
|||
|---|---|---|---|---|---|---|
| 10 years | 20 years | 10 years | 20 years | 10 years | 20 years | |
|
Entire cohort(Median follow-up: 6.0 (IQR 0–29) years) |
14.9 % (13.0–17.0 %) | 25.9 % (22.9–29.0 %) | 9.5 % (7.9–11.2 %) | 18.0 % (15.2–20.8 %) | 6.0 % (4.8–7.5 %) | 9.8 % (7.8–12.1 %) |
| Type of management | ||||||
| No surgery (Median follow-up: 3.0 (IQR 1.4-5.1) years) |
29.1 % (19.5–39.4 %) | 29.1 % (19.5–39.4 %) | 21.3 % (12.7–31.3 %) | 21.3 % (12.7–31.3 %) | 10.0 % (4.4–18.4 %) | 10.0 % (4.4–18.4 %) |
| BCS (Median follow-up: 8.3 (IQR 3.7-15.3 years) |
15.2 % (12.6–18.0 %) | 29.3 % (24.9–33.8 %) | 9.5 % (7.4–11.9 %) | 20.7 % (16.8–25.0 %) | 6.3 % (4.6–8.4 %) | 10.9 % (7.9–14.5 %) |
| Mastectomy (Median follow-up: 9.7 (IQR 4.9-18.1 years) |
6.9 % (3.6–11.5 %) | 9.1 % (5.0–14.8 %) | 0.7 % (0.1–3.5 %) | 0.7 % (0.1–3.5 %) | 6.2 % (3.2–10.7 %) | 8.5 % (4.5–14.1 %) |
| Unknown surgery (Median follow-up: 12.9 (IQR 4.1-21.1 years) | 11.1 % (7.2–16.0 %) | 22.8 % (16.7–29.6 %) | 7.8 % (4.6–12.2 %) | 16.7 % (11.3–23.1 %) | 3.5 % (1.6–6.8 %) | 7.4 % (3.9–12.2 %) |
Median follow-up was calculated from diagnosis of LCIS to IBC event, DCIS, death or last observation. Abbreviations: CIF, cumulative incidence function; CI, confidence interval; IBC, invasive breast cancer; BCS, Breast-conserving surgery; IQR, interquartile range.